Semaglutide fuels rapid growth in US GLP-1RA use as payments rise

https://www.news-medical.net/news/20260720/Semaglutide-fuels-rapid-growth-in-US-GLP-1RA-use-as-payments-rise.aspx As semaglutide became the predominant GLP-1RA, nationally representative data exposed a widening divide between falling patient costs and rising payments from all sources. In a recent study published in the Journal of the American Heart Association, researchers used nationally representative federal survey data to examine trends in glucagon-like peptide-1 receptor agonist (GLP-1RA) utilization and associated payments between 2017 and 2022.